Needham, Mass. — October 3, 2025 — Leads & Copy — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL) will present insights from its enLIGHTEN™ Discovery Platform and data from the CAN-2409 (aglatimagene besadenovec) program in non-small cell lung cancer (NSCLC) at the Society for Immunotherapy of Cancer’s (SITC) 40th Anniversary Annual Meeting, November 5-9, 2025, in National Harbor, Maryland.
Dr. Paul Peter Tak will present phase 3 clinical trial data of CAN-2409 in patients with intermediate-to-high-risk localized prostate cancer as part of an invited faculty presentation and panel discussion on the cancer immunotherapy field.
Poster presentations include:
- Integrative discovery of a multimodal cancer immunotherapy using machine learning and viral vector engineering, presented by Anne Diers, Ph.D., Vice President, Research, Candel Therapeutics.
- Advanced analytics identify a differential immune response to CAN-2409+valacyclovir in non-squamous vs squamous NSCLC, linked to improved survival in patients with progressive ICI-refractory NSCLC, presented by Daniel H. Sterman, M.D., NYU Langone Medical Center.
Dr. Tak will also present on a Phase 3, Randomized, Placebo-Controlled Clinical Trial of CAN-2409 + Prodrug in Combination with Standard of Care Radiation Therapy for Newly Diagnosed, Localized Prostate Cancer with Curative Intent.
Candel is focused on developing off-the-shelf multimodal biological immunotherapies. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 (linoserpaturev) is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma.
Investor Contact:
Theodore Jenkins
Vice President, Investor Relations and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com
Media Contact:
Ben Shannon
Vice President
ICR Healthcare
CandelPR@icrhealthcare.com
Source: Candel Therapeutics, Inc.
